A novel approach for first‐in‐human dose selection using population dose–response modelling to find a minimum anticipated biological effect level
Our novel population modelling-based MABEL strategy for first-in-human dose selection resulted in successful clinical translation of a small molecule STING agonist.
Authors
- Cheryl M. Koh
- Arijit Chakravarty (ORCID: https://orcid.org/0000-0003-1338-5432)
- Evan L. Chiswick (ORCID: https://orcid.org/0000-0003-2869-2101)
- Judy Wang (ORCID: https://orcid.org/0000-0002-7355-7542)
- Péter Sandy
- Melissa L. Johnson (ORCID: https://orcid.org/0000-0001-9874-1314)
- Christopher Winter (ORCID: https://orcid.org/0009-0008-3255-7352)
- Madison Stoddard (ORCID: https://orcid.org/0000-0001-9853-8500)
- Humphrey Gardner
- Gerald S. Falchook (ORCID: https://orcid.org/0000-0001-9165-2191)
- Salah Nabhan
- Woody Sherman (ORCID: https://orcid.org/0000-0001-9079-1376)
- Jennifer E. Johnson (ORCID: https://orcid.org/0000-0003-2540-7213)
- Lin Yuan (ORCID: https://orcid.org/0000-0002-6583-7333)
- Meghana Kulkarni
Institutions
- Silicon Therapeutics (United States) (US)
- Sarah Cannon (US)
- Precision for Medicine (United States) (US)
- Florida Cancer Specialists & Research Institute (US)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2025-04-27
- DOI
- https://doi.org/10.1002/bcp.70067
- Citations
- 1
- Primary Topic
- interferon and immune responses
- Type
- article
- Field-Weighted Citation Impact
- 0.80